Adage Capital Partners
BBIO icon

Adage Capital Partners’s BridgeBio Pharma BBIO Stock Holding History

Adage Capital Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168M Buy
2,252,000
+1,653,000
+276% +$116M 0.24% 73
2026
Q1 		$44.5M Buy
599,000
+90,866
+18% +$6.59M 0.07% 276
2025
Q4 		$38.9M Sell
508,134
-436,712
-46% -$28.7M 0.06% 311
2025
Q3 		$49.1M Buy
944,846
+643,485
+214% +$31.4M 0.08% 243
2025
Q2 		$13M Sell
301,361
-215,194
-42% -$7.83M 0.02% 559
2025
Q1 		$17.9M Buy
516,555
+246,555
+91% +$8.31M 0.03% 448
2024
Q4 		$7.41M Buy
+270,000
New +$6.98M 0.01% 665
2024
Q3 		– Sell
-548,000
Closed -$13.9M – 878
2024
Q2 		$13.9M Buy
548,000
+272,000
+99% +$7.44M 0.03% 529
2024
Q1 		$8.53M Buy
+276,000
New +$9.39M 0.02% 627
2023
Q1 		– Sell
-378,215
Closed -$2.88M – 925
2022
Q4 		$2.88M Buy
378,215
+278,215
+278% +$2.66M 0.01% 795
2022
Q3 		$994K Buy
+100,000
New +$1.04M ﹤0.01% 891

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Adage Capital Partners's BBIO Position: Q2 2026 in Review

Adage Capital Partners increased its BridgeBio Pharma (BBIO) stake by 276% in Q2 2026, buying an estimated $116M and bringing the position to 2,252,000 shares worth $168M. The position accounts for 0.24% of the portfolio, ranked #73.

Adage Capital Partners first reported a position in BBIO in Q3 2022 and has held it in 11 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Adage Capital Partners held 2,252,000 shares of BridgeBio Pharma worth $168M as of Q2 2026.
  • Adage Capital Partners bought 1,653,000 BridgeBio Pharma shares in Q2 2026, an estimated $116M.
  • BridgeBio Pharma made up 0.24% of Adage Capital Partners's portfolio in Q2 2026, its #73 holding.
  • Adage Capital Partners first reported a position in BridgeBio Pharma in Q3 2022 and has held it in 11 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.